Logo

Novacyt: Edwin Snape

Dec 07, 2022

Edwin Snape will retire from the board of directors of Novacyt after 14 years, effective Dec. 31. He was a non-executive director for Novacyt and formerly for Lab21, which Novacyt acquired in 2014. Snape is a cofounder of Nexus NMT Capital, formerly Nexus Medical Partners, and continues to serve as a senior adviser to that firm. He previously served as managing general partner of private equity firm Vista Group and as chairman of private equity firm Orien Ventures. He was also a director of UK-based private equity firm Cygnus Funds and founded pharmaceutical firm The Liposome Company. 

Breaking News
The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.